Also known as: human serum albumin
FDA approved Viridian's Lumvoa (veligrotug-vvze) for thyroid eye disease on June 26, 2026; immediate U.S. launch followed. Q2 2026 cash stood at $982 million, and elegrobart BLA submission is on track for Q1 2027.
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
A retrospective real-world study of 108 Chinese patients with anti-TNF-refractory Crohn’s disease found upadacitinib clinical remission rates of 55.1% at week 12 and 52.5% at week 24.
MIT chemical engineers used a large language model to optimize protein production in industrial yeast. The AI model improved yields for five of six tested proteins, including a cancer monoclonal antibody, potentially reducing drug development costs.
Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
MIT chemical engineers developed a large language model that optimizes codon sequences for protein production in industrial yeast, boosting efficiency for six proteins including human growth hormone and cancer antibodies.
AbbVie filed a lawsuit challenging the federal government's decision to include Botox in Medicare's drug price negotiation program, arguing the drug qualifies as a plasma-derived product excluded under the Inflation Reduction Act.
